* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Inotropic Agents
Drug discovery wikipedia , lookup
Prescription costs wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Discovery and development of integrase inhibitors wikipedia , lookup
Psychopharmacology wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Metalloprotease inhibitor wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug interaction wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Inotropic agents Congestive Heart Failure (CHF) • Heart pumps less blood than it receives, so excess blood pools in the chambers and stretches the walls of the heart Discussion Why is it dangerous for blood to pool in the chambers of the heart? Discussion Why is it dangerous for blood to pool in the chambers of the heart? Answer: decreased oxygen supply to tissues; risk of blood clot formation and movement throughout the body 2 MAIN TYPES of CHF SYSTOLIC CHF – insufficiency of output DIASTOLIC CHF - insufficiency of input CHF • Occurs in 10% of the population over 75 • Can result in death through progressive heart damage or sudden death • Overworking of the heart leads to cardiomegaly and myocardial hypertrophy Causes of Congestive Heart Failure • Primary causes: – Cardiomyopathy – Coronary artery disease – Hypertension • Secondary causes: – High salt intake – Noncompliance with treatment – Side effects of drug therapy – Kidney failure – Stress – Infection and inflammation – Cigarette smoking – Obesity CARDIAC GLYCOSIDES Purple Foxglove Foxglove Lily of the valley Lychnis Chemical structure of cardiac glycosides Pharmacodynamics Cardiac action Extracardiac action Cardiac action • Positive inotropic • Positive bathmotropic • Negative chronotropic • Negative dromotropic Cardiac Glycosides MECHANISM OF CARDIOTONIC (POSITIVE INOTROPIC) ACTION Of CG • • • Promote increasing of Calcium ions concentration in myocardiocytes cytoplasm - Transport of Са inside the cell - Stimulate exit of Са from sarcoplasmic reticulum - Block К, Na-АTP-ase (braking repolarization) Improve usage of macroergic substances by cells, decrease myocardium need in oxygen Increase tone of sympathetic nervous system Extracardiac action of CG • Diuretic • Sedative • Stimulating influence on smooth muscles MODE of ACTION of CG IN CASE OF CHF • Increasing of systolic and minute volumes of heart activity (enhancing cardiac muscle contractility, thus increasing output) • Improving of circulation in lungs and peripheral organs, decreasing volume of blood circulation, excretion of surplus liquid from the organism • Elimination of hypoxia and metabolic acidosis in tissues The following manifestations testify about therapeutic action of CG 1. Improving of general state of the patient (decreasing of weakness, short breath, sleep normalization, disappearing of edema, cyanosis, etc.) 2. Tachycardia transforms into normo (brady)cardia 3. Increasing of diuresis 4. Typical changes in ECG Drug List Agents for CHF • digoxin (Lanoxicaps, Lanoxin) Antidote for digoxin toxicity: • digoxin immune Fab (Digibind) digoxin (Lanoxicaps, Lanoxin) • Increases force of contraction • Increases effective refractory period • Affects SA node, causing direct stimulation digoxin Dispensing Issues Warning! • “dig toxicity” – Systemic accumulation Intoxication with CG Happens frequently 6-23 % Mortality over 40 % Intoxication with CG Cardiac symptoms Worsening of contractive function of myocardium, increasing of circulation insufficiency (18-26 %) Disturbance of heart rhythm (90-95 %, 65 % - single symptom of intoxication) - tachyarrhythmia (increasing of automatism) - blockades - combined disorders of rhythm Intoxication with CG Extracardiac symptoms Gastro-intestinal (40-50 %) Neurological and psychical (25 %) Eye symptoms (65 %) Worsening of kidneys function Drug List Agents for CHF Vasodilators • milrinone (Primacor) • nitroprusside (Nitropress) ACE Inhibitors • Inhibits conversion of angiotensin I to angiotensin II • Lowers blood pressure and lowers the stress on the heart INHIBITORS OF ANGIOTENSINE CONVERTING ENZYME (IACE) In case of CHF they brake pathological consequences of activation of renin-angiotesine system by inhibiting ACE: • production of angiotensine II decreases (vasoconstrictor, inductor of aldosterone, norepinephrine, endothelin secretion, myocardium hypertrophy) • Accumulation of bradikinin (inductor of prostacycline and nitrogen oxide synthesis) INHIBITORS OF ANGIOTESINE CONVERTING ENZYME (IACE) • Increase duration and improve quality of life of patients with CHF • Increase tolerance towards physical loads • Decrease risk of recurring MI • Brake development of myocardium hypertrophy ACE Inhibitor’s Side Effects • Dry, nonproductive cough • Dizziness during first few days ACE Inhibitor Dispensing Issues Warning! • Stand slowly to prevent orthostatic hypotension • Avoid salt substitutes • Do not take potassium supplements Drug List Agents for CHF ACE Inhibitors • • • • • benazepril (Lotensin) captopril (Capoten) enalapril (Vasotec) fosinopril (Monopril) lisinopril (Prinivil, Zestril) Drug List Agents for CHF ACE Inhibitors • • • • • moexipril (Univasc) perindopril (Aceon) quinapril (Accupril) ramipril (Altace) trandolapril (Mavik) Angiotensin II-Receptor Antagonists • Blocks the action of angiotensin II • Works as well as ACE inhibitors with less coughing and better toleration Angiotensin II-Receptor Antagonist Dispensing Issues Warning! • Look-alike and Sound-alike Drugs: – losartan (Cozaar) – valsartan (Diovan) Drug List Agents for CHF Angiotensin II-Receptor Antagonists Human B-type Natriuretic Peptide (hBNP) • nesiritide (Natrecor) NONGLYCOSIDE CARDIOTONIC DRUGS • Dobutamin – beta1-adrenomimetic - in case of acute and chronic CHF – intravenously dropping – 2,5-5-10 mcg/(kg.min); in case of constant infusion tolerance develops after 3-4 days; in case of increasing of dose – heart arrhythmias • Amrinon, milrinon – inhibitors of phosphodiesterase – for temporary improvement of patient’s condition in terminal stages of CHF